8-K: Quoin Files for Breakthrough Status in Saudi Arabia for QRX003

Quoin Pharmaceuticals has applied for Breakthrough Medicine Designation with the SFDA for QRX003, its Netherton Syndrome treatment, potentially accelerating patient access in Saudi Arabia.

Summary

• Quoin Pharmaceuticals Ltd. filed an application for Breakthrough Medicine Designation with the Saudi Food and Drug Authority (SFDA) for QRX003, its lead investigational, late-stage topical product candidate for Netherton Syndrome.
• The SFDA's Breakthrough Medicine Designation program is designed to expedite the development, review, and potential availability of medicines for serious or life-threatening conditions with high unmet medical need.
• Quoin believes that QRX003 meets the SFDA's eligibility requirements for this designation.
• If granted, the designation will allow for accelerated regulatory review and could enable earlier patient access in Saudi Arabia, potentially as early as the second half of 2026.
• QRX003 has previously received Orphan Drug and Pediatric Rare Disease Designations from the U.S. Food and Drug Administration and Orphan Drug Designation from the European Medicines Agency for Netherton Syndrome.
• Quoin has an established distribution partnership with Genpharm for QRX003 for Saudi Arabia and other MENA countries.
• Enrollment in two late-stage whole-body pivotal clinical trials for QRX003 lotion (4%) is expected to be completed in the first half of 2026, with top-line data anticipated in the second half of 2026.
• Quoin plans to submit a New Drug Application (NDA) in the United States and other territories in late 2026/early 2027, subject to successful clinical outcomes.
• As of January 20, 2026, Quoin Pharmaceuticals Ltd. had 1,616,179 American Depositary Shares (ADSs) outstanding, with each ADS representing thirty-five (35) ordinary shares.

Sentiment

Score: 8

Explanation: The filing announces a significant regulatory milestone (application for Breakthrough Medicine Designation) for a lead product candidate targeting a rare disease with no approved treatments. This could significantly accelerate market access and positions the company favorably, indicating strong progress in its development pipeline. The potential for QRX003 to be the first approved treatment globally is a major positive.

Positives

• Application for SFDA Breakthrough Medicine Designation for QRX003, potentially accelerating approval and patient access in Saudi Arabia.
• If granted, QRX003 could be approved for sale and reimbursement in Saudi Arabia as early as 2H 2026.
• QRX003 has the potential to be the first ever approved treatment for Netherton Syndrome globally.
• Existing Orphan Drug and Pediatric Rare Disease Designations from U.S. FDA and Orphan Drug Designation from European Medicines Agency.
• Established distribution partnership with Genpharm for Saudi Arabia and other MENA countries.
• Late-stage clinical trials for QRX003 are progressing, with enrollment expected to complete in 1H 2026 and top-line data in 2H 2026.

Risks

• Actual results may differ materially from forward-looking statements due to various risks and uncertainties.
• Ability to deliver a safe and effective treatment for Netherton Syndrome.
• Ability to pursue regulatory strategy.
• Ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements.
• Ability to complete clinical trials on time and achieve desired results and benefits as expected.
• Experiencing unanticipated or higher than expected clinical trial costs.
• Ability to obtain the capital necessary to fund activities.
• Other factors discussed in the Annual Report on Form 10-K for the year ended December 31, 2024, and in other filings with the SEC.

Future Outlook

Quoin Pharmaceuticals anticipates that if SFDA Breakthrough Medicine Designation is granted for QRX003, it could be approved for sale and reimbursement in Saudi Arabia as early as the second half of 2026. The company expects to complete enrollment in its two late-stage pivotal clinical trials for QRX003 in the first half of 2026, with top-line data expected in the second half of 2026. Subject to successful clinical outcomes, Quoin plans to submit a New Drug Application (NDA) in the United States and other territories in late 2026/early 2027.

Management Comments

• "Filing for Breakthrough Medicine Designation with the SFDA marks a historic milestone for both Quoin and the Netherton Syndrome community."
• "If granted, it is possible that QRX003 could be available for sale and reimbursement in Saudi Arabia in the second half of this year."
• "This would make QRX003 the first ever approved treatment anywhere in the world for this devastating disease."
• "We look forward to working with our commercial partner in the region to make QRX003 available to Netherton patients in Saudi Arabia as expeditiously as possible, if the designation is granted."

Industry Context

This announcement positions Quoin Pharmaceuticals as a leader in developing treatments for rare and orphan diseases, specifically Netherton Syndrome, which currently lacks approved treatments. The pursuit of accelerated regulatory pathways in multiple regions (US, EU, Saudi Arabia) highlights the global unmet medical need for such conditions and the company's strategy to address it. The potential for QRX003 to be the "first ever approved treatment" underscores its significance in the dermatology and rare disease therapeutic areas.

Comparison to Industry Standards

• QRX003's potential to be the "first ever approved treatment" for Netherton Syndrome globally sets a new benchmark, as there are currently no approved therapies for this devastating disease.
• The SFDA's Breakthrough Medicine Designation program, similar to accelerated approval pathways in the U.S. (FDA Breakthrough Therapy) and Europe (EMA PRIME), aims to expedite development for serious conditions with unmet medical needs, aligning Quoin's strategy with global best practices for rare disease drug development.
• The existing Orphan Drug and Pediatric Rare Disease Designations from the U.S. FDA and Orphan Drug Designation from the European Medicines Agency demonstrate QRX003's recognition by major global regulatory bodies for its potential in a rare indication, comparable to other leading rare disease drug candidates.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to accelerated market access, potential first-in-class approval, and progress in the clinical pipeline.
• Patients (Netherton Syndrome): Significant positive impact as QRX003 could become the first approved treatment, offering hope for a devastating disease with high unmet medical need, potentially available in Saudi Arabia as early as 2H 2026.
• Healthcare Providers: New therapeutic option for Netherton Syndrome, addressing a critical unmet need.
• Regulatory Authorities (SFDA): Engagement with the SFDA's Breakthrough Medicine Designation program, potentially validating its effectiveness in expediting critical medicines.
• Commercial Partner (Genpharm): Strengthened partnership and potential for early market entry and revenue generation in Saudi Arabia and MENA region.

Next Steps

• SFDA review of the Breakthrough Medicine Designation application for QRX003.
• Completion of enrollment in two late-stage whole-body pivotal clinical trials for QRX003 in 1H 2026.
• Anticipation of top-line data from QRX003 clinical trials in 2H 2026.
• Potential approval for sale and reimbursement of QRX003 in Saudi Arabia in 2H 2026, if designation is granted.
• Submission of a New Drug Application (NDA) in the United States and other territories in late 2026/early 2027, subject to successful clinical outcomes.
• Working with commercial partner Genpharm to make QRX003 available in Saudi Arabia and other MENA countries.

Key Dates

Recommendation

The application for Breakthrough Medicine Designation for QRX003 in Saudi Arabia, coupled with its existing Orphan Drug designations and late-stage clinical progress, represents a significant de-risking event and a potential acceleration of market entry for a first-in-class treatment for Netherton Syndrome. This could unlock substantial value by addressing a high unmet medical need globally. While regulatory approval is not guaranteed, the designation itself signals strong potential and regulatory alignment, making the stock an attractive "buy" for investors seeking exposure to innovative rare disease therapies with near-term catalysts.

Keywords

Quoin Pharmaceuticals, QNRX, QRX003, Netherton Syndrome, Breakthrough Medicine Designation, SFDA, Saudi Food and Drug Authority, Orphan Drug, Rare Disease, Topical Product, Clinical Trials, NDA, Pharmaceutical, Biotechnology, Dermatology